These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

844 related items for PubMed ID: 18089725

  • 1. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [Abstract] [Full Text] [Related]

  • 2. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
    Hamedani FS, Cinar M, Mo Z, Cervania MA, Amin HM, Alkan S.
    Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
    [Abstract] [Full Text] [Related]

  • 3. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.
    Xu W, Kim JW, Jung WJ, Koh Y, Yoon SS.
    Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J, Yin M, Zhu Y, Gu L, Zhang Y, Li Q, Jia C, Ma Z.
    BMC Cancer; 2013 Oct 10; 13():471. PubMed ID: 24112608
    [Abstract] [Full Text] [Related]

  • 5. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K.
    J Cancer Res Clin Oncol; 2014 Apr 10; 140(4):589-98. PubMed ID: 24509625
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Ceccon M, Merlo MEB, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C.
    Oncogene; 2016 Jul 21; 35(29):3854-3865. PubMed ID: 26657151
    [Abstract] [Full Text] [Related]

  • 8. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F, Cozza G, Cristiani A, Cuzzolin A, Albiero A, Mussolin L, Pillon M, Moro S, Basso G, Rosolen A, Bonvini P.
    PLoS One; 2015 Jul 21; 10(4):e0121378. PubMed ID: 25874976
    [Abstract] [Full Text] [Related]

  • 9. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT, Zhao C, Zhang Q, Wasik MA.
    Blood; 2017 Feb 16; 129(7):823-831. PubMed ID: 27879258
    [Abstract] [Full Text] [Related]

  • 10. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O, Samadi N, Wu C, Lavasanifar A, Lai R.
    Leuk Lymphoma; 2016 May 16; 57(5):1154-62. PubMed ID: 26133723
    [Abstract] [Full Text] [Related]

  • 11. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C, Molavi O, Zhang H, Gupta N, Alshareef A, Bone KM, Gopal K, Wu F, Lewis JT, Douglas DN, Kneteman NM, Lai R.
    Blood; 2015 Jul 16; 126(3):336-45. PubMed ID: 25921060
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
    Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P, Giuriato S.
    Oncotarget; 2015 Oct 06; 6(30):30149-64. PubMed ID: 26338968
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
    Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG.
    Cancer Res; 2007 May 01; 67(9):4408-17. PubMed ID: 17483355
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, Shetty B.
    J Pharmacol Exp Ther; 2012 Mar 01; 340(3):549-57. PubMed ID: 22129595
    [Abstract] [Full Text] [Related]

  • 19. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
    Zhang J, Wang P, Wu F, Li M, Sharon D, Ingham RJ, Hitt M, McMullen TP, Lai R.
    Cell Signal; 2012 Apr 01; 24(4):852-8. PubMed ID: 22155737
    [Abstract] [Full Text] [Related]

  • 20. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y, Wang K, Song N, Hou K, Che X, Zhou Y, Liu Y, Zhang J.
    Invest New Drugs; 2020 Jun 01; 38(3):599-609. PubMed ID: 31177400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.